OKT3 first-line treatment of acute rejection episodes following combined pancreas and kidney transplantation.
Cantarovich
D
D
Service de Néphrologie, Nantes University Hospital, France.
Hourmant
M
M
Dantal
J
J
Giral
M
M
Paineau
J
J
Karam
G
G
Soulillou
J P
JP
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery*; D003928:Diabetic Nephropathies / Q000601:surgery*; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D016035:Pancreas Transplantation / Q000276:immunology*; D011239:Prednisolone / Q000627:therapeutic use
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D016572:Cyclosporine; D011239:Prednisolone; D001379:Azathioprine